NSE - Delayed Quote INR

Divi's Laboratories Limited (DIVISLAB.NS)

3,929.00 -2.15 (-0.05%)
At close: 12:29 PM GMT+5:30
Loading Chart for DIVISLAB.NS
DELL
  • Previous Close 3,931.15
  • Open 3,887.05
  • Bid --
  • Ask --
  • Day's Range 3,870.00 - 3,965.00
  • 52 Week Range 3,051.00 - 4,100.00
  • Volume 31,964
  • Avg. Volume 507,193
  • Market Cap (intraday) 1.043T
  • Beta (5Y Monthly) 0.38
  • PE Ratio (TTM) 75.54
  • EPS (TTM) 52.01
  • Earnings Date May 18, 2024 - May 22, 2024
  • Forward Dividend & Yield 30.00 (0.77%)
  • Ex-Dividend Date Aug 11, 2023
  • 1y Target Est 4,951.17

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, North America, Asia, Europe, and internationally. It also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.

www.divislabs.com

8,433

Full Time Employees

March 31

Fiscal Year Ends

Recent News: DIVISLAB.NS

Performance Overview: DIVISLAB.NS

Trailing total returns as of 5/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DIVISLAB.NS
0.64%
S&P BSE SENSEX
2.44%

1-Year Return

DIVISLAB.NS
21.20%
S&P BSE SENSEX
20.22%

3-Year Return

DIVISLAB.NS
0.89%
S&P BSE SENSEX
49.26%

5-Year Return

DIVISLAB.NS
149.90%
S&P BSE SENSEX
95.11%

Compare To: DIVISLAB.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DIVISLAB.NS

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    1.04T

  • Enterprise Value

    1.00T

  • Trailing P/E

    75.05

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.04

  • Price/Book (mrq)

    8.19

  • Enterprise Value/Revenue

    13.56

  • Enterprise Value/EBITDA

    43.81

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.46%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    74.93B

  • Net Income Avi to Common (ttm)

    13.83B

  • Diluted EPS (ttm)

    52.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    36.11B

  • Total Debt/Equity (mrq)

    0.04%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: DIVISLAB.NS

Company Insights: DIVISLAB.NS

Research Reports: DIVISLAB.NS

People Also Watch